tradingkey.logo

OraSure Technologies Inc

OSUR

3.300USD

+0.010+0.30%
Close 09/18, 16:00ETQuotes delayed by 15 min
243.33MMarket Cap
LossP/E TTM

OraSure Technologies Inc

3.300

+0.010+0.30%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
47 / 207
Overall Ranking
159 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
6.000
Target Price
+86.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 19.50M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is -4.81, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.08M shares, decreasing 18.81% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.17M shares of this stock.

Financial Health

Currency: USD Updated2025-09-17

The company's current financial score is 7.15, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 31.24M, representing a year-over-year decrease of 42.50%, while its net profit experienced a year-over-year decrease of 3102.11%.

Score

Industry at a Glance

Previous score
7.15
Change
0

Financials

9.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.98

Operational Efficiency

6.13

Growth Potential

5.61

Shareholder Returns

7.11

Company Valuation

Currency: USD Updated2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -4.81, which is -343.99% below the recent high of 11.74 and -35.49% above the recent low of -6.52.

Score

Industry at a Glance

Previous score
2.00
Change
-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-17

The company’s current earnings forecast score is 7.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for OraSure Technologies Inc is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score
7.33
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts
Buy
Current Rating
6.000
Target Price
+82.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
OraSure Technologies Inc
OSUR
3
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-17

The company’s current price momentum score is 8.78, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 3.63 and the support level at 2.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.31
Change
1.47

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(5)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.003
Neutral
RSI(14)
56.288
Neutral
STOCH(KDJ)(9,3,3)
55.511
Neutral
ATR(14)
0.129
High Vlolatility
CCI(14)
45.777
Neutral
Williams %R
46.377
Neutral
TRIX(12,20)
0.372
Sell
StochRSI(14)
78.718
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
3.270
Buy
MA10
3.276
Buy
MA20
3.241
Buy
MA50
3.132
Buy
MA100
2.990
Buy
MA200
3.292
Buy

Institutional Confidence

Currency: USD Updated2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 98.55%, representing a quarter-over-quarter increase of 5.09%. The largest institutional shareholder is The Vanguard, holding a total of 4.17M shares, representing 5.70% of shares outstanding, with 0.57% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Private Management Group, Inc.
4.42M
--
BlackRock Institutional Trust Company, N.A.
5.58M
+0.50%
The Vanguard Group, Inc.
Star Investors
4.29M
+1.44%
Neuberger Berman, LLC
4.28M
+18.00%
Dimensional Fund Advisors, L.P.
3.82M
-3.72%
Renaissance Technologies LLC
Star Investors
2.57M
-7.33%
Systematic Financial Management, L.P.
1.65M
-1.58%
Acadian Asset Management LLC
2.76M
-4.98%
American Century Investment Management, Inc.
2.51M
+6.79%
1
2

Risk Assessment

Currency: USD Updated2025-09-17

The company’s current risk assessment score is 3.82, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.82
Change
0
Beta vs S&P 500 index
0.47
VaR
+4.71%
240-Day Maximum Drawdown
+44.77%
240-Day Volatility
+60.63%
Return
Best Daily Return
60 days
+10.83%
120 days
+10.83%
5 years
+32.29%
Worst Daily Return
60 days
-8.49%
120 days
-9.11%
5 years
-23.50%
Sharpe Ratio
60 days
+0.96
120 days
+0.16
5 years
-0.21
Risk Assessment
Maximum Drawdown
240 days
+44.77%
3 years
+70.90%
5 years
+84.24%
Return-to-Drawdown Ratio
240 days
-0.46
3 years
-0.12
5 years
-0.18
Skewness
240 days
-0.95
3 years
+0.83
5 years
+0.97
Volatility
Realised Volatility
240 days
+60.63%
5 years
+56.88%
Standardised True Range
240 days
+4.79%
5 years
+9.07%
Downside Risk-Adjusted Return
120 days
+26.05%
240 days
+26.05%
Maximum Daily Upside Volatility
60 days
+53.01%
Maximum Daily Downside Volatility
60 days
+35.22%
Liquidity
Average Turnover Rate
60 days
+0.96%
120 days
+0.93%
5 years
--
Turnover Deviation
20 days
-22.48%
60 days
-12.47%
120 days
-15.15%

Peer Comparison

Healthcare Equipment & Supplies
OraSure Technologies Inc
OraSure Technologies Inc
OSUR
6.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI